1. Context
Adhesion step and sessile aggregation of a biofilm (5)
2. Evidence Acquisition
3. Results
3.1. Significance of Biofilms in Clinical Settings
| Variables | Values |
|---|---|
| General aspect of clinical signs | (In some cases) low-grade fever, loss of function, dolor, low-grade inflammatory reactions tumor, and rubor; Implanted medical device and cystic fibrosis (CF) disease as the medical history of biofilm-predisposing situations; All persistent and lasting (> 7 days) infections, antibiotic resistance during treatment; Infection relapse and antibiotic treatment defeat; Documented record /antibiotic defeat background; All systemic signs and infection symptoms resolve with antibiotic therapy. |
| Microbiological diagnostics | A- Microscopic evidence of tissue/ fluid samples gathered from suspected infection location; Microscopic evidence disclosing microbial aggregates by the examination of fluid sample or smear; Microscopic evidence Microscopic evidence disclose microbial co-localized together with inflammatory cells; Microbiological document confirm with infectious etiology |
| B- Microbial microorganisms indicated by a few procedures (e.g., positive culture/non-culture-based (PCR) of tissue or liquid example) | Microbial pathogens detected by culture (MALDI-TOF); Mucoid settlements or variations of Pseudomonas aeruginosa small colony in culture-positive examples, indicating anti-infection disobedience; Positive outcomes detected by a few molecular techniques (e.g., PCR, quantitative PCR, or multiplex PCR for microbes related to contamination with P. aeruginosa and CF, Staphylococcus aureus related to contamination with implant); The positive outcome of fluorescence in situ hybridization for well-known pathogens displaying snuggled microorganisms; Microbial pathogen detected by several non-culture-based techniques such as next-generation sequencing, pyrosequencing, specific immune reaction to known bacteria such as P. aeruginosa antigens in patients with CF (if infections induced by biofilm last for about 2 weeks.) |
| Anatomic site A with normal flora | Anatomic site B without normal flora |
|---|---|
| Skin; Pharynx; Duodenum; Urethra; Vagina; Air in operating room, skin flora | Blood, peritoneum; Bronchi, lungs; Bile tract, pancreas; Bladder; Uterus; Neurosurgical shunt, alloplastic material |
| No symptoms | Pathology |
| Device | Infection |
|---|---|
| Peritoneal dialysis catheters | Exit-sit-infections, peritonitis |
| Hemodialysis catheters | Access site infections, endocarditis, bacteremia |
| Urinary catheters | Urinary tract infections, bacteremia |
| Intravenous catheters | Access site infections, bacteremia |
| Prosthetic cardiac valves | Prosthetic valve endocarditis, bacteremia |
| CSF shunts and reservoirs | Access site infection, meningitis |
| Cardiac pacemakers | Lead and generator infections, endocarditis |
| Contact lenses | Conjunctivitis, endophthalmitis |
| Surgical sutures & staples | Urinary tract infections |
| Infection | Common Biofilm-Producing Bacteria |
|---|---|
| Musculoskeletal infections, acidogenic enzymes of dental caries plaque | Gram-positive cocci (e.g., Streptococcus) |
| Serious gum infection (periodontitis) | Oral anaerobic bacilli (Gram-negative) |
| Inflammatory diseases of middle ear or otitis media (OM) | Haemophilus influenzae (nontypable strains) |
| Necrotizing fasciitis (NF) | Group A streptococci |
| ICU pneumonia, biliary tract infection, urinary catheter cystitis, bacterial prostatitis | Enterobacteriaceae |
| Endocarditis of native valve | VGS (viridans group streptococci) |
| Cystic fibrosis (CF), meloidosis | Pseudomonadaceae |
| Scleral buckles, vascular grafts | Cocci (especially Gram-positive) |
| Ocular prosthetic devices, such as contact lens | Cocci (especially Gram-positive), and Pseudomonas aeruginosa |
| Continuous ambulatory peritoneal dialysis, osteomyelitis, endotracheal tubes, peritonitis | Wide assortment of microbes, fungi |
| IUDs | Actinomyces israelii and wide assortment of microbes |
| Hickman line, central venous catheters (CVC) | Staphylococcus epidermidis, Candida albicans, and others |
| Bile duct stent | Enterobacteriaceae, fungi |
| Method | Application | Objectives |
|---|---|---|
| Roll plate | Identification of extra-luminal biofilm | Bacterial growth related to biofilm |
| Plate counting, Sonication, vortex and | Identification of intra-luminal, and extra-luminal biofilm | Bacterial growth related to biofilm |
| Staining by acridine orange | Identification of extra-luminal biofilm | Direct investigation microscopy of biofilm on catheter |
| Streak plating | Biofilm examination delivered on an inhabiting catheter | Bacterial growth related to biofilm |
3.2. Antibiotic Drug Resistance
3.3. Diagnosis: Assays and Lab Devices of Biofilm Formation Evaluation
| Method | Aim |
|---|---|
| TM | Tube method: A qualitative method monitoring biofilm formation lined on tube walls and bottom. |
| CRA | Congo red agar: A qualitative method monitoring the color change of colony. |
| MtP | Microtiter plate: A quantitative method using micro ELISA or microplate reader. |
| PCR (including real-time, conventional, and multiplex) | Identification of biofilm-producing genes |
| Method | Application | Objective |
|---|---|---|
| MtP | Microtiter plate: Biofilm produced on wells’ walls in response to agent | Agent measurement effects on biofilm production |
| MBEC | Minimum biofilm eradication concentration: Biofilm detection created on wells’ walls in response to agent and identifying agents MBEC | Agent measurement effects on the production of mature biofilms on wells’ walls |
| Vortex accompanied with plate counting | Plate counting of bacterial growth induced by biofilms and detecting MBEC agents | Screening antimicrobial agents’ activity against bacterial growth induced by biofilms |
| Checkerboard assay | Plate counting of bacterial growth induced by biofilms and calculating FIC indices | Antimicrobial activity screening of a combination of agents |
| Sonication accompany with vortex, and plate counting | Detecting biofilm produced on wells’ walls in response to agent and identifying MBEC agents | Screening the activity of antimicrobial agents against bacterial growth induced by biofilm |
| Quantitative PCR | Measuring specific biofilm gene expression | Gene expression induced by biofilm and monitoring expression in response to agents |
| MS | Mass spectrometry: Located exoenzymes measurement in biofilm matrix | Bacterial protein monitoring expression in response to agents |
| Devices | Substratum | Type of Culture | Screening Counting Method |
|---|---|---|---|
| Modified Robbins | Silastic disks | Batch | Viable (36) |
| Disk reactor | Teflon coupons | Batch | Viable or direct, after sonicating, vortexing, and homogenizing coupons (36) |
| Calgary biofilm | Plastic polycarbonate pegs | Batch | Viable, after sonicating of pegs (36) |
| Flow cell | Chambers with transparent surfaces | Continuous | Confocal laser scanning microscopy (36) |
| Perfused biofilm fermenter | Cellulose-acetate filters | Continuous | Viable, after shaking filters in sterile distilled water (36) |
| CDC biofilm reactor | Plastic connectors | Continuous | Growth medium continuous flow for biofilm formation of glass coupons by sonicating coupons individually (36) |
| Model bladder | Urinary catheters | Continuous | Direct examination by chemical analysis or SEM or TEM (36). |
| Nuclease-based fluorescence | - | - | Some indirect detection methods for example end-point staining methods by crystal violet in microtiter well plates or tubes to screen attached bacteria on extracellular polysaccharides target surfaces (56) |
| Fluorescence-based real-time screening | - | - | Direct investigation of new antibiofilm agents/surfaces in a continuous mode against biofilms (57) |
3.4. Therapeutic Approaches
| Method | Function |
|---|---|
| Catheters covered with antibiotics or hydrogels | They are hydrophilic polymers making the catheter capable of increasing surface lubrication and consequently reducing the bacterial adhesion to this surface, thereby playing a role in decreasing the encrustation of catheters; An increase > 45% in CAUTI is perceived by silver alloy employment in a urinary catheter covered by hydrogel (65, 66); It is proved that catheters covered with minocycline-rifampicin stop biofilm formation in Gram-negative and Gram-positive bacteria, Candida spp. and even P. aeruginosa (67) |
| Antibiofilm treatments by nanoparticles | These particles can stick and penetrate into bacterial cells, damage the bacterial membrane, and act with chromosomal DNA(68); Biofilm formation blockage in E. coli and S. aureus strains by glass surfaces coating with MgF nanoparticles is observed. Yttrium fluoride (YF3) nanoparticles have low solubility, extended protection, and low cytotoxicity (69); CaO-NPs (microwave irradiated CaO nanoparticles) have the potential to inhibit the biofilm production of Gram-negative and Gram-positive bacteria (70); Silver nanoparticles are applied for coating medical devices because of the silver antibacterial attributes. These nanoparticles, as part of biosensors, have been used in medical and pharmaceutical nano-engineering for diagnostic approaches, transfer, and therapeutic agents (71). |
| Iontophoresis | Iontophoresis, a physical process in a medium where ions stream diffusively, applies as an experimental, diagnostic, and therapeutic method. It uses voltage gradients as a kind of transdermal drug delivery procedure. It was proved that low electrical currents increase he tactivity of tobramycin and biocides against biofilm producing P. aeruginosa (72); Iontophoresis inhibit biofilm formation. Electric current use to these catheters covered by silver electrodes remarkably decreased their formation (73, 74). |
| Biofilm-degrading enzyme | A new antibiofilm urease induced by P. mirabilis convert change urea to ammonium ions; fluorofamide can prohibit the enhancement in pH by Proteus mirabilis, thereby preventing the urea crystal formation and the subsequent encrustation and catheter blockage; vanillic acid (75), natural plum juice, and germa-γ-lactones (76) can forcefully prevent bacterial growth of crystal formation in catheters by inhibiting urease enzymes; DspB, an enzyme pertaining to the bacteriophage and extracted from Actinobacillus species, ruin a crucial adhesion essential for biofilm production in E. coli and Staphylococcus (77); c-di-GMP is the second messenger significantly conserved among bacteria. It decreases biofilm production by reducing c-di-GMP inside cells (78). |
| Antagonism among different bacteria | Antagonism can cause with using different E. coli avirulent strains (79, 80) such as E. coli, HU2117 strain originated from E. coli 83972. Avirulent strains can colonize persistently without any symptomatic infection (81); hence, it has been applied for urinary catheters to reduce of biofilm production by other pathogenic strains (80). In individuals with an intermittent catheterization, a decrease in the development of UTIs is reported. |
| Bacteriophages | Specifically, lytic phages (the natural predators of bacteria) can infect bacteria, interrupt the normal bacterial metabolism (especially the biofilms of P. mirabilis and E. coli), and support viral replication (82); phages of S. aureus (83) with bactericidal activity control biofilm formation by replicating at infection site and depolymerize the destruction of the biofilm EPS matrix (84, 85). |
| Quorum sensing (QS) inhibitors | QS is a kind of relationship among bacterial cells responding to extracellular signaling molecules, called autoinducers (AIs) (86). AIs, small signal molecules proportional to cell-density related to gene expression (87), can regulate several processes involved in virulence such as motility and biofilm formation (88). This is necessary for planktonic bacteria to present the biofilm phenotype. An effective QSI inhibitor should have some characteristics, as described below (89): A, capable of excluding gene expression pertaining to QS by a low molecular mass; B, significant specificity for QS regulators; C, No toxicity foreukaryotic cells, D, non-interference with the fundamental bacterial metabolic processes to elude the resistance development; E, chemically permanent, resistant to the host metabolism, and inhabiting in the host cell for a long time; HSL, N-acyl homoserine lactone, is analogous to the QS signal. It can emulates blocking QS, with signals to receptor binding, and prohibit the biofilm formation of S. aureus (90). Garlic extract can enhance the susceptibility against tobramycin by modifying the architecture of bacterial biofilms (91). Moreover, peptides display the QSI activity; The RNAIII-preventing peptide is capable of prohibiting agr-mediated biofilm production in drug resistant S. epidermidis (90, 92). |
| Low-energy surface acoustic waves (SAW) | SAW intervenes with planktonic microorganisms’ adhesion to cellular surfaces (88). It has been applied for urinary catheters to reduce of biofilm production by other pathogenic strains (93, 94). |
| Antiadhesive compounds/molecules | It should specifically interact with the adhesions of pathogen and prohibit the union among pathogen and eukaryotic cell. It decreases invasion or host cells infection and eludes reversion; Cranberry produces a proanthocyanidin trimer in the extract and has an anti-adherence effect against uropathogenic E. coli (UPEC). Other antiadhesion agents are pilicides, mannosides, and curlicides (43). |
